(E)-(1-(4-ethoxycarbonylphenyl)-5-(3,4-dimethoxyphe nyl)-3-(3,4-dimethoxystyryl)-2-pyrazoline: Synthesis, characterization, dna-interaction, and evaluation of activity against drug-resistant cell lines

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3077991 13 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
(E)-(1-(4-ethoxycarbonylphenyl)-5-(3,4-dimethoxyphe nyl)-3-(3,4-dimethoxystyryl)-2-pyrazoline: Synthesis, characterization, dna-interaction, and evaluation of activity against drug-resistant cell lines
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
(E)-1-(4-Ethoxycarbonylphenyl)-5-(3,4-dimethoxyphenyl)-3-(3,4-dimethoxystyryl)-2-pyrazoline was synthesized via the cyclization reaction between the monocarbonyl curcuminoid (2E,6E)-2,6-bis(3,4-dimethoxybenzylidene)acetone and ethyl hydrazinobenzoate in high yield and purity (>95% by High-performance liquid chromatography (HPLC)). The compound has been fully characterized by1H,13C NMR, FTIR, UV-Vis and HRMS and its activity was evaluated in terms of its potential interaction with DNA as well as its cytotoxicity against resistant and non-resistant tumor cells. Both DNA thermal denaturation and DNA viscosity measurements revealed that a significant intercalation binding takes place upon treatment of the DNA with the synthesized pyrazoline, causing an increase in melting temperature by 3.53 ± 0.11 °C and considerable DNA lengthening and viscosity increase. However, neither re-sensitisation of Doxorubicin (DO X)-resistant breast cancer and multidrug resistance (MDR) reversal nor synergistic activity with DOX by potentially increasing the DOX cell killing ability was observed. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Έτος δημοσίευσης:
2020
Συγγραφείς:
Matiadis, D.
Mavroidi, B.
Panagiotopoulou, A.
Methenitis, C.
Pelecanou, M.
Sagnou, M.
Περιοδικό:
MolBank
Εκδότης:
MDPI AG
Τόμος:
2020
Αριθμός / τεύχος:
1
Επίσημο URL (Εκδότης):
DOI:
10.3390/M1114
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.